Please find details below of how Clinigen intends to mitigate the risk of supply disruption as the UK exits the current transitional trading period with the EU planned for the end of 2020. While there is uncertainty over the UK’s future trade relationship with the EU, we are following MHRA guidance issued throughout September & October to ensure we will be able to provide a continuous service. This guidance states that there will be no change to the current process (MHRA Guidance note 14) and unlicensed medicines will be imported into the UK in the same way they are today, irrespective of whether they are supplied from the EEA or outside the EEA.
As mentioned in previous correspondence, Clinigen has been and continues to increase stock levels in our UK warehouses to ensure continued and future supply is aligned with current Department of Health and Social Care (DHSC) guidance, and in addition continues to play a key role in supporting the DHSC in managing ongoing and new UK supply shortages. If you have any questions or there are specific products you wish clarification on to meet your patients on-going needs, then please do not hesitate to contact us at Clinigen UK Customer Service team on +44 (0)1932 824100 or E-mail: firstname.lastname@example.org